Stock Scorer

Entrada Therapeutics, Inc. (TRDA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 35M 70M 105M Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q1 '23: 25.3M Q2 '23: 18.2M Q3 '23: 43.7M Q4 '23: 41.8M Q1 '24: 59.1M Q2 '24: 94.7M Q3 '24: 19.6M Q4 '24: 37.4M Q1 '25: 20.6M Q2 '25: 1.9M Q3 '25: 1.6M Q4 '25: 1.3M Q1 '26: 875K Q2 '26: 898K Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -14.4M Q4 '21: -18.5M Q1 '22: -22.2M Q2 '22: -23.6M Q3 '22: -25.9M Q4 '22: -25.6M Q1 '23: -5.8M Q2 '23: -16.3M Q3 '23: 14M Q4 '23: 4.9M Q1 '24: 21.1M Q2 '24: 53.4M Q3 '24: -21.7M Q4 '24: -5.9M Q1 '25: -21.8M Q2 '25: -46.8M Q3 '25: -47.1M Q4 '25: -42.2M Q1 '26: -42.3M Q2 '26: -45M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -14.4M Q4 '21: -18.4M Q1 '22: -21.7M Q2 '22: -23.2M Q3 '22: -25.1M Q4 '22: -24.6M Q1 '23: -6.7M Q2 '23: -25.9M Q3 '23: 35.5M Q4 '23: -9.5M Q1 '24: 23.5M Q2 '24: 55M Q3 '24: -14M Q4 '24: 1.1M Q1 '25: -17.3M Q2 '25: -43.1M Q3 '25: -44.1M Q4 '25: -39.2M Q1 '26: -39.7M Q2 '26: -42.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-70M 0 70M 140M 210M Q3 '21: -14.1M Q4 '21: -20.5M Q1 '22: -21M Q2 '22: -18M Q3 '22: -27.5M Q4 '22: -27.3M Q1 '23: 203.4M Q2 '23: -35.1M Q3 '23: -24.5M Q4 '23: -4M Q1 '24: -25.5M Q2 '24: 39.8M Q3 '24: -24.3M Q4 '24: -31.6M Q1 '25: -38.5M Q2 '25: -29.5M Q3 '25: -28.3M Q4 '25: -32.2M Q1 '26: -41.7M Q2 '26: -32.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-70M 0 70M 140M 210M Q3 '21: -14.9M Q4 '21: -21.9M Q1 '22: -21.6M Q2 '22: -18.8M Q3 '22: -28.3M Q4 '22: -28M Q1 '23: 201.7M Q2 '23: -36.6M Q3 '23: -25.9M Q4 '23: -5M Q1 '24: -26.4M Q2 '24: 38.8M Q3 '24: -24.9M Q4 '24: -32.2M Q1 '25: -39.7M Q2 '25: -29.8M Q3 '25: -28.5M Q4 '25: -32.4M Q1 '26: -41.7M Q2 '26: -32.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '20: 1.1M Q1 '21: 1.3M Q2 '21: 1.3M Q3 '21: 1.5M Q1 '22: 31.2M Q2 '22: 31.3M Q3 '22: 31.3M Q1 '23: 32.4M Q2 '23: 33.2M Q3 '23: 34.8M Q1 '24: 34.8M Q2 '24: 35.5M Q3 '24: 40.6M Q1 '25: 41.1M Q2 '25: 41.3M Q3 '25: 41.5M Q1 '26: 41.8M Q2 '26: 42.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q3 '21: -31.46 Q4 '21: -8.16 Q1 '22: -2.18 Q2 '22: 4.64 Q3 '22: 13.62 Q4 '22: -3.01 Q1 '23: -2.53 Q2 '23: -2.57 Q3 '23: -0.75 Q4 '23: -0.20 Q1 '24: 0.69 Q2 '24: 3.02 Q3 '24: 1.65 Q4 '24: 1.68 Q1 '25: 0.58 Q2 '25: -2.01 Q3 '25: -2.72 Q4 '25: -3.46 Q1 '26: -3.99 Q2 '26: -3.96 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for TRDA: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.